Predictions
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€52.24
22.11.23
22.11.23
-
22.11.24
22.11.24
0.50%
12.12.23
12.12.23
Bluebird Bio Inc.
Start price
Target price
Perf. (%)
€4.00
02.12.23
02.12.23
€5.00
31.10.25
31.10.25
-30.50%
10.12.23
10.12.23
Could be very worthwhile Investment >20% year
Teladoc Health Inc
Start price
Target price
Perf. (%)
€16.80
29.11.23
29.11.23
€20.00
29.11.24
29.11.24
6.55%
09.12.23
09.12.23
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€51.82
25.11.23
25.11.23
-
25.11.24
25.11.24
1.27%
09.12.23
09.12.23
Arrowhead Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€19.62
30.11.23
30.11.23
-
30.11.24
30.11.24
12.62%
08.12.23
08.12.23
Could be very worthwhile Investment >20% year
Charles River Labs Intl
Start price
Target price
Perf. (%)
€212.90
03.12.22
03.12.22
€255.00
03.12.23
03.12.23
-13.20%
03.12.23
03.12.23
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€95.50
26.11.22
26.11.22
-
26.11.23
26.11.23
-45.74%
27.11.23
27.11.23
PTC Therapeutics Inc.
Start price
Target price
Perf. (%)
€17.20
28.10.23
28.10.23
€8.00
28.10.24
28.10.24
-4.07%
11.11.23
11.11.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
negative Cash Flow expected
Integra LifeSciences Holdings Corp
Start price
Target price
Perf. (%)
€44.40
26.10.22
26.10.22
€48.00
26.10.23
26.10.23
-24.77%
26.10.23
26.10.23
Syneos Health, Inc.
Start price
Target price
Perf. (%)
€49.56
25.10.22
25.10.22
€50.00
25.10.23
25.10.23
-17.27%
26.10.23
26.10.23
Medpace Holdings Inc
Start price
Target price
Perf. (%)
€218.90
25.10.22
25.10.22
€190.00
25.10.23
25.10.23
11.47%
26.10.23
26.10.23
Could be worthwhile Investment >10% per year
Mirati Therapeutics Inc.
Start price
Target price
Perf. (%)
€59.10
05.10.23
05.10.23
-
05.10.24
05.10.24
-8.93%
15.10.23
15.10.23
Could be worthwhile Investment >10% per year
Acadia Pharmaceuticals
Start price
Target price
Perf. (%)
€19.60
30.09.23
30.09.23
€9.00
30.09.24
30.09.24
11.22%
14.10.23
14.10.23
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Lower EBIT Margin than peer group